Plain-English translation of NCT07405970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called can help people with systemic lupus erythematosus (an autoimmune disease where the body attacks its own tissues). Researchers will compare the medication to a placebo (a dummy treatment with no active ingredient) to see if it reduces lupus symptoms and flares. About 316 people will participate in this Phase 3 trial, which is an advanced stage of testing before a medication can be approved.
Lupus is a serious condition that can cause joint pain, rashes, fatigue, and organ damage, and many patients need better treatment options. This study is testing whether this new antibody-based medication might offer people with lupus another way to control their disease and improve their quality of life.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either or a placebo injection at regular visits over several months. You will need to have blood tests and check-ins to monitor how the medication is working and whether you experience any side effects. The study will track your lupus symptoms and disease activity to see if the treatment helps reduce flares and improve how you feel.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Beijing Mabworks Biotech Co., Ltd.
Enrollment target
~316 participants
Started
April 2026
Primary completion
December 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhanguo Li
Beijing Mabworks Biotech Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.